To print: Select File and then Print from your browser's menu

Title: Combined Doxorubicin/Cisplatin Increases Response Rate In Endometrial Adenocarcinoma

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12598351&dopt=Abstract

Annals of Oncology, 2003;14:3:441-448. "Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group."
03/04/2003 02:43:39 PM
By Elda Hauschildt

Combining doxorubicin with cisplatin produces a significantly higher response rate in patients with endometrial adenocarcinoma than does doxorubicin monotherapy, research from Switzerland indicates. Investigators from Hopital Cantonal Universitaire in Geneva report a modest survival benefit is achieved, especially in patients who have a good performance status. Median overall survival was nine months in combination therapy patients and seven months in monotherapy patients. They add that toxicity is higher but acceptable with combination therapy. A total of 177 patients with histologically proven advanced and/or recurrent endometrial adenocarcinoma were enrolled. Median follow-up was 7.1 years. Participants were chemotherapy naïve. Treatment was administered every four weeks. It was made up of either 60 mg/m² doxorubicin alone or with 50 mg/m² of cisplatin added. Results indicate 39 patients (43%) receiving doxorubicin/cisplatin responded, including 13 with complete responses and 26 with partial responses. This compared with 15 patients (17%) who responded to doxorubicin monotherapy. A total of eight monotherapy patients were complete responders and seven had partial responses. Combination therapy was more toxic. White blood cell toxicity grades 3 and 4 occurred in 55% of combination therapy patients and in 30% of monotherapy patients. There were two main forms of non-haematological toxicity. Grades 3 and 4 alopecia occurred in 72% of combination therapy patients and in 65% of monotherapy patients. Nausea/vomiting was observed in 36% of combination therapy patients and 12% of monotherapy patients. World Health Organisation performance status was found to be statistically significant as a prognostic factor for survival.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12598351&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.